source
- ADARx, backed by AbbVie, files for IPO to fund clinical-stage siRNA programsADARx Pharmaceuticals, a San Diego biotech supported by AbbVie, announced plans to pursue an initial public offering. The company says most of the IPO proceeds will be used to advance three clinic…
- AbbVie’s dual-acting myeloma drug etentamig meets main Phase 3 goal, showing longer progression-free survivalAbbVie announced that its bispecific antibody etentamig achieved the primary endpoint in a Phase 3 trial for patients with multiple myeloma who have progressed after two or more prior therapies. Th…